These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 24184771

  • 1. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
    Li Q, Su Z, Liu J, Cai L, Lu J, Lin S, Xiong Z, Li W, Zheng W, Wu J, Zhuge Q, Wu Z.
    Mol Cell Endocrinol; 2014 Jan 25; 382(1):377-384. PubMed ID: 24184771
    [Abstract] [Full Text] [Related]

  • 2. [Inhibitory effect of adenovirus-mediated D2S gene plus bromocriptine therapy on primary cultures of human non-functioning pituitary adenoma cells].
    Xiong ZK, Li WQ, Liu J, Wu ZB, Li Q, Chen YX, Su ZP, Wu JS.
    Zhonghua Yi Xue Za Zhi; 2012 Oct 23; 92(39):2739-42. PubMed ID: 23290158
    [Abstract] [Full Text] [Related]

  • 3. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.
    BMC Endocr Disord; 2021 Nov 23; 21(1):235. PubMed ID: 34814904
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells.
    Su Z, Jiang X, Wang C, Liu J, Chen Y, Li Q, Wu J, Zheng W, Zhuge Q, Jin K, Wu Z.
    Endocrine; 2012 Dec 23; 42(3):670-5. PubMed ID: 22684586
    [Abstract] [Full Text] [Related]

  • 5. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
    Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A.
    Neuroendocrinology; 1994 Sep 23; 60(3):314-22. PubMed ID: 7969790
    [Abstract] [Full Text] [Related]

  • 6. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.
    Geng X, Ma L, Li Z, Li Z, Li J, Li M, Wang Q, Chen Z, Sun Q.
    World Neurosurg; 2017 Apr 23; 100():407-416. PubMed ID: 28137551
    [Abstract] [Full Text] [Related]

  • 7. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas.
    Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Müller A, Lange M, Weindl A, Stalla GK.
    J Clin Endocrinol Metab; 1998 Apr 23; 83(4):1368-75. PubMed ID: 9543168
    [Abstract] [Full Text] [Related]

  • 8. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L, Leng ZG, Guo YH, Lin SJ, Wu ZR, Su ZP, Lu JL, Wei LF, Zhuge QC, Jin K, Wu ZB.
    Endocrine; 2016 Jun 23; 52(3):641-51. PubMed ID: 26662185
    [Abstract] [Full Text] [Related]

  • 9. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.
    Oomizu S, Boyadjieva N, Sarkar DK.
    Alcohol Clin Exp Res; 2003 Jun 23; 27(6):975-80. PubMed ID: 12824819
    [Abstract] [Full Text] [Related]

  • 10. Induction of apoptosis in rat somatotrophin-secreting pituitary adenoma cells by bromocriptine.
    Yin D, Kondo S, Takeuchi J, Morimura T.
    Oncol Res; 1993 Jun 23; 5(9):383-7. PubMed ID: 8038459
    [Abstract] [Full Text] [Related]

  • 11. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma.
    Eljarmak D, Lis M, Cantin M, Carrière PD, Collu R.
    Horm Res; 1985 Jun 23; 21(3):160-7. PubMed ID: 3997065
    [Abstract] [Full Text] [Related]

  • 12. Estrogen inhibits D2S receptor-regulated Gi3 and Gs protein interactions to stimulate prolactin production and cell proliferation in lactotropic cells.
    Sengupta A, Sarkar DK.
    J Endocrinol; 2012 Jul 23; 214(1):67-78. PubMed ID: 22573829
    [Abstract] [Full Text] [Related]

  • 13. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ, Culler MD, Pawlikowski M.
    Life Sci; 2006 Jan 11; 78(7):689-93. PubMed ID: 16115652
    [Abstract] [Full Text] [Related]

  • 14. Effects of bromocriptine on hormone production and cell growth in cultured rat pituitary cells.
    Johansen PW, Haug E, Gautvik KM.
    Acta Endocrinol (Copenh); 1985 Oct 11; 110(2):200-6. PubMed ID: 4060970
    [Abstract] [Full Text] [Related]

  • 15. Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis.
    Al-Azzawi H, Yacqub-Usman K, Richardson A, Hofland LJ, Clayton RN, Farrell WE.
    Endocrinology; 2011 Feb 11; 152(2):364-73. PubMed ID: 21177832
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R.
    Endocrinology; 2013 Mar 11; 154(3):1247-59. PubMed ID: 23384836
    [Abstract] [Full Text] [Related]

  • 17. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z, Liu Q, Li C, Zong X, Bai J, Wu Y, Lan X, Yu G, Zhang Y.
    Mol Cell Endocrinol; 2015 Feb 15; 402():64-71. PubMed ID: 25578603
    [Abstract] [Full Text] [Related]

  • 18. Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells.
    Bondioni S, Angioni AR, Corbetta S, Locatelli M, Ferrero S, Ferrante E, Mantovani G, Olgiati L, Beck-Peccoz P, Spada A, Lania AG.
    Exp Biol Med (Maywood); 2008 Apr 15; 233(4):439-46. PubMed ID: 18367633
    [Abstract] [Full Text] [Related]

  • 19. Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines.
    Wang X, Du Q, Mao Z, Fan X, Hu B, Wang Z, Chen Z, Jiang X, Wang Z, Lei N, Wang H, Zhu Y.
    Oncotarget; 2017 Jul 11; 8(28):45874-45887. PubMed ID: 28501857
    [Abstract] [Full Text] [Related]

  • 20. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
    Tang C, Zhu J, Yuan F, Yang J, Cai X, Ma C.
    Mol Neurobiol; 2021 Dec 11; 58(12):6170-6185. PubMed ID: 34463926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.